Identifying genomic and developmental causes of adverse drug reactions in children

Pharmacogenomics

Volumn 11, Issue 11, 2010, Pages 1591-1602

  Becker, Mara L ^a   Leeder, J Steven ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

adverse drug reactions; genetic variants; methotrexate; pediatrics; pharmacogenomics

Indexed keywords

2 PROPYL 4 PENTENOIC ACID; ACETYLSALICYLIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; AZATHIOPRINE; CATECHOL METHYLTRANSFERASE; CEFACLOR; CHLORAMPHENICOL; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; FUROSEMIDE; LAMOTRIGINE; MERCAPTOPURINE; METHOTREXATE; PAROXETINE; PROMETHAZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; VALPROIC ACID;

ABSENCE; ADAPTATION SYNDROME; ADVERSE DRUG REACTION; BIPOLAR DISORDER; CATALYSIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TRANSFORMATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE MUTATION; GENERALIZED EPILEPSY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IRRITABILITY; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; MIGRAINE; MUSCLE TONE; MYOCLONUS EPILEPSY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NERVOUSNESS; ONTOGENY; OTOTOXICITY; PEDIATRICS; PH; PHARMACOGENOMICS; PRESCRIPTION; PROTEIN EXPRESSION; REVIEW; REYE SYNDROME; RISK FACTOR; SEROTONIN SYNDROME; SERUM SICKNESS; SIDE EFFECT; SKIN TOXICITY; TACHYPNEA; TONIC CLONIC SEIZURE; TREMOR; WEIGHT GAIN;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; BIOTRANSFORMATION; CHILD; DRUG TOXICITY; GENOMICS; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 78649691288     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.146     Document Type: Review

References (88)

1. WHO: International drug monitoring: the role of national centres. In: Tech. Rep. Serv. WHO, No. 498. Geneva, Switzerland (1972).
2. Edwards IR, Aronson JK: Adverse drug reactions: defnitions, diagnosis, and management. Lancet 356, 1255-1259 (2000).
3. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: J. Am. Med. Assoc. 279, 1200-1205 (1998).
4. Wester K, Jonnson AK, Sigset O, Druid H, Hagg S: Incidence of fatal adverse drug reactions: a population base study. Br. J. Clin. Pharmacol. 65, 573-579 (2008).
5. Davies EC, Green CF, Tayloe S, Williamson PR, Mottram DR, Pirmohamed M: Adverse drug reactions in hospital in-patients: a prospective ana lysis of 3695 patient-episodes. PLoS ONE 4, e4439 (2009).
6. Aranda JV: Factors associated with adverse drug reactions in the newborn. Ped. Pharmacol. 3, 245-249 (1983).
7. Mitchell AA, Lacouture PG, Sheehan JE, Kauffman RE, Shapiro S: Adverse drug reactions in children leading to hospital admission: Pediatrics 82, 24-29 (1988).
8. Martínez-Mir I, García-López M, Palop V et al.: A prospective study of adverse drug reactions in hospitalized children. Br. J. Clin. Pharmacol. 47, 681-688 (1999).
9. Gonzalez-Martin G, Caroca CM, Paris E: Adverse drug reactions (ADRs) in hospitalized pediatric patients: a prospective study. Int. J. Clin. Pharmacol. Ther. 36, 530-533 (1998).
10. Kaushal R, Bates DW, Landrigan C et al.: Medication errors and adverse drug events in pediatric inpatients. JAMA 285, 2114-2120 (2001).
11. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfni C, Bonati M: Incidence of adverse drug reactions in pediatric in/out-patients: a systematic review and meta-ana lysis of prospective studies. Br. J. Clin. Pharmacol. 52, 77-83 (2001).
12. Carleton B, Poole R, Milton J, Travis J, Grinder D: The pediatric adverse drug reaction reporting system: J. Pediatr. Pharm. Pract. 4, 284-307 (1999).
13. Takata GS, Mason W, Taketomo C, Logsdon T, Sharek PJ: Development, testing, and fndings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals. Pediatrics 121, e927-e935 (2008).
14. Johann-Liang R, Wyeth J, Chen M, Cope JU: Pediatric drug surveillance and the food and drug administration's adverse event reporting system: an overview of reports, 2003-2007. Pharmacoepidemiol. Drug Saf. 18, 24-27 (2009).
15. Rodriguez W, Roberts R, Murphy D: Adverse drug events in children: the US Food and Drug Administration persepctive. Curr. Ther. Res. 62, 711-723 (2001).
16. Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI: Evaluation of a [13C]- dextromethorphan breath test to assess CYP2D6 phenotype. J. Clin. Pharmacol. 48(9), 1041-1051 (2008).
17. Dreifuss FE, Santilli RN, Langer DH, Sweeney KP, Moline KA, Menander KB: Valproic acid hepatic fatalaties: a retrospective review. Neurology 37, 379-385 (1987).
18. Dreifuss FE, Langer DH, Moline KA, Maxwell JE: Valproic acid hepatic fatalities: II. US experience since 1984. Neurology, 39, 201-207 (1989).
19. Bryant AE, Dreifuss FE: Valproic acid hepatic fatalities: III. U.S. experience since 1986. Neurology, 46, 465-469 (1996).
20. Reinblatt SP, DosReis S, Walkup JT, Riddle MA: Activation adverse events induced by the selective serotonin reuptake inhibitor fuvoxamine in children and adolescents. J. Child Adolesc. Psychopharmacol. 19(2), 119-126 (2009).
21. Guberman AH, Besag FMC, Brodie MJ et al.: Lamotrigine-induced rash: risk/beneft considerations in adults and children. Epilepsia 40, 985-991 (1999).
22. Messenheimer JA: Rash in adult and pediatric patients treated with lamotrigine. Can. J. Neurol. Sci. 25, S14-S18 (1998).
23. Relling MV, Rubnitz JE, Rivera GK et al.: High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354, 34-39 (1999).
24. Relling MV, Boyett JM, Blanco JG et al.: Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101, 3862-3867 (2003).
25. Wagner-Weiner L: Pediatric rheumatology for the adult rheumatologist. J. Clin. Rheumatol. 14, 109-119 (2008).
26. Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB: Reye's syndrome in the United States from 1981 through 1997. N. Engl. J. Med. 340, 1377-1382 (1999).
27. Kearns GL, Wheeler JG, Childress SH, Letzig LG: Serum sickness-like reactions to cefaclor: Role of hepatic metabolism and individual susceptibility. J. Pediatr. 125, 805-811 (1994).
28. Kassahun K, Farrell K, Abbott FS: Identifcation and characterization of the glutathione and Nacetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab. Disp. 19, 525-535 (1991).
29. Kassahun K, Abbott FS: In vivo formation of the thiol conjugates of reactive metabolites of 4-ene-VPA and its analogue 4-pentenoic acid. Drug Metab. Disp. 21, 1098-1106 (1993).
30. Rettenmeier AW, Prickett KS, Gordon WP et al.: Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid: Evidence for the formation of chemically reactive intermediates. Drug Metab. Disp. 13, 81-96 (1985).
31. Baillie TA: Metabolic activation of valproic acid and drug-mediated hepatotoxicity: role of the terminal olefn, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1, 195-199 (1988).
32. Safer DJ, Zito JM: Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J. Child Adolesc. Psychopharmacol. 16(1-2), 159-169 (2006).
33. Labellarte M, Biederman J, Emslie G et al.: Multiple-dose pharmacokinetics of fuvoxamine in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 43(12), 1497-1505 (2004).
34. Agunod M, Yamaguchi N, Lopez R, Luhby AL, Glass GB: Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am. J. Dig. Dis. 14(6), 400-414 (1969).
35. Moazam F, Kirby WJ, Rodgers BM, McGuigan JE: Physiology of serum gastrin production in neonates and infants. Ann. Surg. 199(4), 389-392 (1984).
36. Gupta M, Brans YW: Gastric retention in neonates: Pediatrics 62(1), 26-29 (1978).
37. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003).
38. Hines RN: The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol. Ther. 118(2), 250-267 (2008).
39. Papadopoulou ZL, Leticia TU, Sandler P, Jose PA, Calcagno PL: Children Are Different: Developmental Physiology (2nd Edition). Johnston TR, MaJJ W (Ed.) Ross Laboratories, OH, USA, 99 (1978).
40. Mulla H: Understanding developmental pharmacodynamics: importance for drug development and clinical practice. Paediatr. Drugs 12(4), 223-233 (2010).
41. Burns LE, Hodgman JE, Cass AB: Fatal circulatory collapse in premature infants receiving chloramphenicol. N. Engl. J. Med. 261, 1318-1321 (1959).
42. Lambdin MA, Waddell WW, Birdsong M: Chloramphenicol toxicity in the premature infant: Pediatrics 25, 935-940 (1960).
43. Weiss CF, Glazko AJ, Weston JK: Chloramphenicol in the newborn infant: a physiologic explanation of its toxicity when given in excessive doses. N. Engl. J. Med. 262, 787-794 (1960).
44. Chen M, LeDuc B, Kerr S, Howe D, Williams DA: Identifcation of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. Drug Metab. Dispos. 38(3), 368-375 (2010).
45. De Wildt SN, Kearns GL, Leeder JS, Van den Anker JN: Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin. Pharmacokinet. 36(6), 439-452 (1999).
46. Innocenti F, Liu W, Fackenthal D et al.: Single nucleotide polymorphism discovery and functional assessment of variation in the UDP- glucuronosyltransferase 2B7 gene. Pharmacogenet. Genomics 18(8), 683-697 (2008).
47. Lancaster T, Swart AM, Jick H: Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database. BMJ 316(7132), 667 (1998).
48. Stiskal JA, Kulin N, Koren G, Ho T, Ito S: Neonatal paroxetine withdrawal syndrome. Arch. Dis. Child. Fetal Neonatal Ed. 84, F134-F135 (2001).
49. Mhanna MJ, Bennet JB, Izatt SD: Potential fuoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 100, 158-159 (1997).
50. Spencer MJ: Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 92, 721-722 (1993).
51. Lane R, Baldwin D: Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. Clin. Psychopharmacol. 17, 208-221 (1997).
52. Laine K, Kytölä J, Bertilsson L: Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther. Drug Monit. 26, 685-687 (2004).
53. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM: Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol. Psychiatry. 13(1), 65-73 (2008).
54. Leeder JS: Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology. Clin. Pharmacol. Ther. 86(6), 678-682 (2009).
55. Leeder JS, Kearns GL, Spielberg SP, Van den Anker J: Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J. Clin. Pharmacol. 50(12), 1377-1387 (2010).
56. Blake MJ, Gaedigk A, Pearce RE et al.: Ontogeny of dextromethorphan O- and N -demethylation in the frst year of life. Clin. Pharmacol. Ther. 81(4), 510-516 (2007).
57. Stevens JC, Marsh SA, Zaya MJ et al.: Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos. 36(8), 1587-1593 (2008).
58. Allegaert K, Van den Anker JN, Verbesselt R et al.: O-demethylation of tramadol in the frst months of life. Eur. J. Clin. Pharmacol. 61(11), 837-842 (2005).
59. Chládek J, Zimová G, Martínková J, Tuma I: Intra-individual variability and infuence of urine collection period on dextromethorphan metabolic ratios in healthy subjects. Fund. Clin. Pharmacol. 13, 508-511 (1999).
60. Jones DR, Gorski JC, Hamman MA, Hall SD: Quantifcation of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J. Chromatogr. B. 678, 105-111 (1996).
61. Ganiere-Monteil C, Medard Y, Lejus C et al.: Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur. J. Clin. Pharmacol. 60(2), 89-96 (2004).
62. Park-Hah JO, Klemetsdal B, Lysaa R, Choi KH, Aarbakke J: Thiopurine methyltransferase activity in a Korean population sample of children. Clin. Pharmacol. Ther. 60(1), 68-74 (1996).
63. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S -methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001-2008 (1999).
64. Ooi CY, Bohane TD, Lee D, Naidoo D, Day AS: Thiopurine metabolite monitoring in paediatric infammatory bowel disease. Aliment Pharmacol. Ther. 25(8), 941-947 (2007).
65. Stocco G, Cheok MH, Crews KR et al.: Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of me rcaptop urine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85(2), 164-172 (2009).
66. Aldenkamp A, VigeVano F, Arzimanoglou A, CoVanis A: Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol. Scand. 114(Suppl. 184), 1-13 (2006). (Pubitemid 43882144)
67. Welty TE: Juvenile myoclonic epilepsy: epidemiology, pathophysiology and management. Paediatr. Drugs 8, 303-310 (2006).
68. Azorin JM, Findling RL: Valproate use in children and adolescents with bipolar disorder. CNS Drugs 21, 1019-1033 (2007).
69. Eiland LS, Jenkins LS, Durham SH: Pediatric migraine: pharmacologic agents for prophylaxis. Ann. Pharmacother. 41, 1181-1190 (2007).
70. Koenig SA, Buesing D, Longin E et al.: Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994-2003. Epilepsia 47, 2027-2031 (2006).
71. König SA, Siemes H, Bläker F et al.: Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 35, 1005-1015 (1994).
72. Scheffner D, König S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S: Fatal liver failure in 16 children with valproate therapy. Epilepsia 29, 530-542 (1988).
73. Zimmerman HJ, Ishak KG: Valproate- induced hepatic injury: ana lysis of 23 fatal cases. Hepatology 2, 591-597 (1982).
74. Gopaul SV, Farrell K, Abbott FS: Gas chromatography/negative ion chemical ionization mass spectrometry and liquid chromatography/electrospray ionization tandem mass spectrometry quantitative profling of N-acetylcysteine conjugates of valproic acid in urine: application in drug metabolism studies in humans. J. Mass Spectrom. 35, 698-704 (2000).
75. Gopaul SV, Farrell K, Abbott FS: Identifcation and characterization of Nacetylcysteine conjugates of valproic acid in humans and animals. Drug Metab. Disp. 28, 823-832 (2000).
76. Cassidy P, Lindsley C, Laxer R (Eds): Textbook of Pediatric Rheumatology. Saunders, USA (2005).
77. Becker ML RC, Cron RQ, Sherry DD, Bilker WB, Lautenbach E: Effectiveness and toxicity of methotrexate in juvenile idiopathic athritis: comparison of two initial dosing regimens. J. Rheumatol. 37(4), 870-875 (2010).
78. Ranganathan P: An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents. Curr. Opin Mol. Ther. 10(6), 562-567 (2008).
79. Everens WE, Schentag JJ, Jusko WJ, Harrison H (Eds): Applied Pharmacokinetics: Principles Of Therapeutic Drug Monitoring. In: Applied Therapeutics. Lippincott Williams & Wilkins, NY, USA (1986).
80. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG: Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J. Biol. Chem. 279(24), 25527-25534 (2004).
81. Becker ML, Van Haandel L, Gaedigk R et al.: Analysis of intracellular methotrexate polyglutamates in juvenile idiopathic arthritis: effect of route of administration upon intracellular methotrexate polyglutamate variability. Arthritis Rheum. 62(6), 1803-1812 (2010).
82. Dervieux T, Kremer J, Lein DO et al.: Contribution of common polymorphisms in reduced folate carrier and y-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14(11), 733-739 (2004).
83. Dervieux T, Furst D, Lein DO et al.: Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann. Rheum. Dis. 64(8), 1180-1185 (2005).
84. Dervieux T, Greenstein N, Kremer J: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 54(10), 3095-3103 (2006).
85. Loebstein R, Koren G: Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatr. Rev. 19(12), 423-428 (1998).
86. Becker LM, Gaedigk R, Van Haandel L et al.: The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. DOI: 10.1002/ art.30080 (2010) (Epub ahead of print).
87. Carleton BC, Poole RL, Smith MA et al.: Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol. Drug Safety 18, 718-721 (2009).
88. Ross CJ, Katzov-Eckert H, Dube MP et al.: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41(12), 1345-1349 (2009).